Figure 6.

A GR Antagonist and a Cortisol-Lowering Drug Impede Growth of Xenograft Models of Ewing Sarcoma

(A) RD-ES cells (2 × 10⁶) were implanted subcutaneously in the flanks of SCID mice. Once tumors reached 150 mm³, animals were randomized into three groups (n = 10) that were daily treated intraperitoneally with vehicle, DEX (1 mg/kg), or RU486 (1 mg/kg) and tumorigenic growth was monitored. The means of tumor volumes (+SEM) are shown. Statistical analysis of tumor volumes (day 12) is indicated (RU486 group versus DEX or vehicle).

(B) Representative images of immunofluorescent KI67 staining in paraffin-embedded tumor sections from (A). Scale bars, 100 μm. The scatterplot depicts quantification of KI67 staining in 4 fields of a representative tumor from each group.

(C and D) A673 cells (2 × 10⁶) were implanted in female SCID mice. Once tumors reached 150 mm³, animals were randomized into two groups (n = 9). Each group was daily treated with either vehicle or metyrapone (25 mg/kg).

(C) Actual tumor volumes (±SEM) are presented.

(D) Also shown are tumors harvested from each group of animals; ^∗∗∗p < 0.001.

(E and F) STA-ET-11 cells (2 × 10⁶) were implanted subcutaneously in SCID mice. Once tumors reached 150 mm³, animals were randomized into three groups (5 mice per group), which were daily treated intraperitoneally with vehicle, DEX (1 mg/kg), or RU486 (1 mg/kg). (E) The means of tumor volumes (+SEM) are shown along with (F) statistical analysis of tumor volumes measured on day 73.